NEUROCRINE BIOSCIENCES INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
NEUROCRINE BIOSCIENCES INC (NBIX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$57.05 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-30.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-04-30
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$57.05M, a 200.36% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$59.28M, a 493.42% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$35.39M, a 181.93% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$213.04M.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$250.87M, a 322.28% decline from fiscal 2016.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $112.86M.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$195.81M.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$105.37M, a 2073.15% decline from fiscal 2013.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | -$57.05M 10-Q · filed 2018-04-30 | -$116.33M derived: sum of 2 quarters · filed 2018-04-30 | -$151.72M derived: sum of 3 quarters · filed 2018-04-30 | -$364.77M derived: sum of 4 quarters · filed 2018-04-30 | |
| 2017-12-31 | -$59.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$94.67M derived: sum of 2 quarters · filed 2018-02-13 | -$307.72M derived: sum of 3 quarters · filed 2018-02-13 | -$250.87M 10-K · filed 2018-02-13 | |
| 2017-09-30 | -$35.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$248.44M derived: sum of 2 quarters · filed 2017-11-01 | -$191.59M 10-Q · filed 2017-11-01 | -$176.52M derived: sum of 4 quarters · filed 2018-04-30 | |
| 2017-06-30 | -$213.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$156.20M 10-Q · filed 2017-08-03 | -$141.13M derived: sum of 3 quarters · filed 2018-04-30 | -$97.93M derived: sum of 4 quarters · filed 2018-04-30 | |
| 2017-03-31 | $56.85M 10-Q · filed 2018-04-30 | $56.65M 10-Q · filed 2017-05-09 | $71.91M derived: sum of 2 quarters · filed 2018-04-30 | $115.11M derived: sum of 3 quarters · filed 2018-04-30 | $99.45M derived: sum of 4 quarters · filed 2018-04-30 |
| 2016-12-31 | $15.07M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $58.26M derived: sum of 2 quarters · filed 2018-02-13 | $42.61M derived: sum of 3 quarters · filed 2018-02-13 | $112.86M 10-K · filed 2018-02-13 | |
| 2016-09-30 | $43.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $27.54M derived: sum of 2 quarters · filed 2017-11-01 | $97.80M 10-Q · filed 2017-11-01 | $119.85M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-06-30 | -$15.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $54.60M 10-Q · filed 2017-08-03 | $76.65M derived: sum of 3 quarters · filed 2018-02-13 | $28.79M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-03-31 | $70.25M 10-Q · filed 2017-05-09 | $92.31M derived: sum of 2 quarters · filed 2018-02-13 | $44.45M derived: sum of 3 quarters · filed 2018-02-13 | -$9.46M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2015-12-31 | $22.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$25.81M derived: sum of 2 quarters · filed 2018-02-13 | -$79.72M derived: sum of 3 quarters · filed 2018-02-13 | -$195.81M 10-K · filed 2018-02-13 | |
| 2015-09-30 | -$47.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$101.77M derived: sum of 2 quarters · filed 2016-11-02 | -$217.87M 10-Q · filed 2016-11-02 | -$202.32M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2015-06-30 | -$53.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$170.01M 10-Q · filed 2016-08-03 | -$154.46M derived: sum of 3 quarters · filed 2017-02-14 | -$151.25M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2015-03-31 | -$116.09M 10-Q · filed 2016-05-05 | -$100.55M derived: sum of 2 quarters · filed 2017-02-14 | -$97.33M derived: sum of 3 quarters · filed 2017-02-14 | -$155.73M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2014-12-31 | $15.54M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $18.76M derived: sum of 2 quarters · filed 2017-02-14 | -$39.63M derived: sum of 3 quarters · filed 2017-02-14 | -$105.37M 10-K · filed 2017-02-14 | |
| 2014-09-30 | $3.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | -$55.18M derived: sum of 2 quarters · filed 2015-10-29 | -$120.91M 10-Q · filed 2015-10-29 | -$100.18M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-06-30 | -$58.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-29 | -$124.13M 10-Q · filed 2015-07-29 | -$103.40M derived: sum of 3 quarters · filed 2016-02-11 | -$104.70M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-03-31 | -$65.73M 10-Q · filed 2015-04-30 | -$45.00M derived: sum of 2 quarters · filed 2016-02-11 | -$46.31M derived: sum of 3 quarters · filed 2016-02-11 | -$25.31M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2013-12-31 | $20.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $19.42M derived: sum of 2 quarters · filed 2016-02-11 | $40.42M derived: sum of 3 quarters · filed 2016-02-11 | $5.34M 10-K · filed 2016-02-11 | |
| 2013-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $19.69M derived: sum of 2 quarters · filed 2014-11-04 | -$15.39M 10-Q · filed 2014-11-04 | ||
| 2013-06-30 | $20.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | -$14.08M 10-Q · filed 2014-08-06 | |||
| 2013-03-31 | -$35.08M 10-Q · filed 2014-05-01 | ||||
| 2012-12-31 | -$34.76M 10-K · filed 2015-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |